Rifaximin for pertuzumab-related GI toxicities

Aixa E. Soyano, Gina Reynolds, Alvaro Moreno Aspitia, Saranya Chumsri

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pertuzumab is a monoclonal antibody against HER2. Diarrhea and abdominal pain are common adverse events of pertuzumab-based therapy, occurring in almost 70% of patients. The incidence of gastrointestinal toxicities intensifies when pertuzumab is given in combination with chemotherapy. Rifaximin, a non-absorbable oral antibiotic, may provide symptomatic relief in patients with refractory gastrointestinal toxicities from pertuzumab-based therapy beyond standard routine antidiarrheal medications. We present a case of HER2-related therapy-induced diarrhea and abdominal pain managed successfully with Rifaximin.

Original languageEnglish (US)
Pages (from-to)168
Number of pages1
JournalFrontiers in Oncology
Volume7
Issue numberAUG
DOIs
StatePublished - Aug 8 2017

Fingerprint

rifaximin
Abdominal Pain
Diarrhea
Antidiarrheals
Combination Drug Therapy
Therapeutics
Monoclonal Antibodies
Anti-Bacterial Agents
pertuzumab
Incidence

Keywords

  • Diarrhea
  • Gastrointestinal toxicities
  • HER2 positive breast cancer
  • Pertuzumab
  • Rifaximin
  • Trastuzumab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Rifaximin for pertuzumab-related GI toxicities. / Soyano, Aixa E.; Reynolds, Gina; Moreno Aspitia, Alvaro; Chumsri, Saranya.

In: Frontiers in Oncology, Vol. 7, No. AUG, 08.08.2017, p. 168.

Research output: Contribution to journalArticle

Soyano, Aixa E. ; Reynolds, Gina ; Moreno Aspitia, Alvaro ; Chumsri, Saranya. / Rifaximin for pertuzumab-related GI toxicities. In: Frontiers in Oncology. 2017 ; Vol. 7, No. AUG. pp. 168.
@article{86b499585dea4f919102dcf810bbca41,
title = "Rifaximin for pertuzumab-related GI toxicities",
abstract = "Pertuzumab is a monoclonal antibody against HER2. Diarrhea and abdominal pain are common adverse events of pertuzumab-based therapy, occurring in almost 70{\%} of patients. The incidence of gastrointestinal toxicities intensifies when pertuzumab is given in combination with chemotherapy. Rifaximin, a non-absorbable oral antibiotic, may provide symptomatic relief in patients with refractory gastrointestinal toxicities from pertuzumab-based therapy beyond standard routine antidiarrheal medications. We present a case of HER2-related therapy-induced diarrhea and abdominal pain managed successfully with Rifaximin.",
keywords = "Diarrhea, Gastrointestinal toxicities, HER2 positive breast cancer, Pertuzumab, Rifaximin, Trastuzumab",
author = "Soyano, {Aixa E.} and Gina Reynolds and {Moreno Aspitia}, Alvaro and Saranya Chumsri",
year = "2017",
month = "8",
day = "8",
doi = "10.3389/fonc.2017.00168",
language = "English (US)",
volume = "7",
pages = "168",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",
number = "AUG",

}

TY - JOUR

T1 - Rifaximin for pertuzumab-related GI toxicities

AU - Soyano, Aixa E.

AU - Reynolds, Gina

AU - Moreno Aspitia, Alvaro

AU - Chumsri, Saranya

PY - 2017/8/8

Y1 - 2017/8/8

N2 - Pertuzumab is a monoclonal antibody against HER2. Diarrhea and abdominal pain are common adverse events of pertuzumab-based therapy, occurring in almost 70% of patients. The incidence of gastrointestinal toxicities intensifies when pertuzumab is given in combination with chemotherapy. Rifaximin, a non-absorbable oral antibiotic, may provide symptomatic relief in patients with refractory gastrointestinal toxicities from pertuzumab-based therapy beyond standard routine antidiarrheal medications. We present a case of HER2-related therapy-induced diarrhea and abdominal pain managed successfully with Rifaximin.

AB - Pertuzumab is a monoclonal antibody against HER2. Diarrhea and abdominal pain are common adverse events of pertuzumab-based therapy, occurring in almost 70% of patients. The incidence of gastrointestinal toxicities intensifies when pertuzumab is given in combination with chemotherapy. Rifaximin, a non-absorbable oral antibiotic, may provide symptomatic relief in patients with refractory gastrointestinal toxicities from pertuzumab-based therapy beyond standard routine antidiarrheal medications. We present a case of HER2-related therapy-induced diarrhea and abdominal pain managed successfully with Rifaximin.

KW - Diarrhea

KW - Gastrointestinal toxicities

KW - HER2 positive breast cancer

KW - Pertuzumab

KW - Rifaximin

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=85027129988&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85027129988&partnerID=8YFLogxK

U2 - 10.3389/fonc.2017.00168

DO - 10.3389/fonc.2017.00168

M3 - Article

VL - 7

SP - 168

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

IS - AUG

ER -